Sign up to save your podcasts
Or
Share PIDTC Immune Matters - Episode 5 Emapalumab
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
PIDTC Immune Matters - Episode 5 Emapalumab
In this episode of Immune Matters, hosts Jack McDonnell and Elie Haddad speak with Dr. Joseph Oved, a pediatric hematologist-oncologist and transplant specialist at Columbia University, about the biologic therapy emapalumab (Gamifant). The discussion explores how this anti–interferon-gamma monoclonal antibody is used to treat hyperinflammatory conditions such as primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome.
Dr. Oved explains the underlying immunology of interferon-gamma–driven inflammation and how targeted blockade of this pathway can interrupt the cycle of immune dysregulation. The conversation also examines emerging applications of emapalumab in hematopoietic stem cell transplantation, including its potential role in preventing graft rejection, managing hyperinflammation, and improving transplant outcomes in patients with inborn errors of immunity.
The episode concludes with a discussion of ongoing research, the importance of precision medicine in immune dysregulation disorders, and new PIDTC initiatives that allow clinicians to collaborate on complex cases and share expertise across institutions.
Note: for more information on how you can get the PIDTC's help with a complex case, please email [email protected] or [email protected] .
Keywords: emapalumab, Gamifant, HLH, macrophage activation syndrome, interferon-gamma, hyperinflammation, hematopoietic stem cell transplant, graft rejection, inborn errors of immunity, PIDTC, immune dysregulation, biologics, precision medicine, clinical immunology
View all episodes
By Jack McDonnellIn this episode of Immune Matters, hosts Jack McDonnell and Elie Haddad speak with Dr. Joseph Oved, a pediatric hematologist-oncologist and transplant specialist at Columbia University, about the biologic therapy emapalumab (Gamifant). The discussion explores how this anti–interferon-gamma monoclonal antibody is used to treat hyperinflammatory conditions such as primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome.
Dr. Oved explains the underlying immunology of interferon-gamma–driven inflammation and how targeted blockade of this pathway can interrupt the cycle of immune dysregulation. The conversation also examines emerging applications of emapalumab in hematopoietic stem cell transplantation, including its potential role in preventing graft rejection, managing hyperinflammation, and improving transplant outcomes in patients with inborn errors of immunity.
The episode concludes with a discussion of ongoing research, the importance of precision medicine in immune dysregulation disorders, and new PIDTC initiatives that allow clinicians to collaborate on complex cases and share expertise across institutions.
Note: for more information on how you can get the PIDTC's help with a complex case, please email [email protected] or [email protected] .
Keywords: emapalumab, Gamifant, HLH, macrophage activation syndrome, interferon-gamma, hyperinflammation, hematopoietic stem cell transplant, graft rejection, inborn errors of immunity, PIDTC, immune dysregulation, biologics, precision medicine, clinical immunology